Skip to main content

Table 2 Compliance with chemotherapy

From: Dose-intense capecitabine, oxaliplatin and bevacizumab as first line treatment for metastatic, unresectable colorectal cancer: a multi-centre phase II study

  Total C1750 mg/m2 C1500 mg/m2
  n = 49 n = 19 n = 30
Reason for discontinuation of chemotherapy, n (%)    
Progression 12 (24.5) 4 (21.1) 8 (26.7)
Need for surgery 6 (12.2) 2 (10.5) 4 (13.3)
Death (treatment-related cause) 3 (6.1) 1 (5.3) 2 (6.7)
Other toxicity 16 (32.7) 5 (26.3) 11(36.7)
Patient or investigator decision not otherwise specified 11 (22.4) 7 (36.8) 4 (13.3)
Still on treatment 1 (2.0) 0 (0.0) 1 (3.3)
Receipt ofat least 75% of planned dose in first two cycles, n (%)    
Each drug separately    
Capecitabine 42 (85.7) 18 (94.7) 24 (80.0)
Oxaliplatin 46 (93.9) 19 (100.0) 27 (90.0)
Bevacizumab 44 (89.8) 17 (89.5) 27 (90.0)
All three drugs 40 (82.6) 16 (84.0) 24 (80.0)
Dose intensity while on chemotherapy, median (IQ range)   
Capecitabine 0.95 (0.66, 1) 0.8(0.57,1) 0.96 (0.67,1)
Oxaliplatin 1 (0.8, 1) 0.8 (0.67,1) 1 (1,1)
Bevacizumab 1 (0.8, 1) 0.8 (0.67,1) 1 (1,1)